SCHEMBL379630

SCHEMBL379630

O=C(O)CC(O)Cc1ccc(-c2ccccc2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP12 P39900 5/20 0.70
MMP13 P45452 3/20 0.70
MMP2 P08253 1/20 0.70
MMP9 P14780 1/20 0.70
MMP14 P50281 1/20 0.70
FFAR1 O14842 1/20 0.56
SRR Q9GZT4 2/20 0.56
PSAT1 Q9Y617 2/20 0.56
ABCC4 O15439 1/20 0.55
LMNA P02545 1/20 0.55
GAA P10253 1/20 0.55
TSHR P16473 1/20 0.55
PTGS1 P23219 1/20 0.55
HTT P42858 1/20 0.55
PPARG P37231 6/20 0.54
PPARA Q07869 5/20 0.54
MMEL1 Q495T6 1/20 0.54
TRPA1 O75762 1/20 0.53
TRPV1 Q8NER1 1/20 0.50
CPA1 P15085 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6800633 1.00 MMP12 (0.70) MMP12MMP13MMP2MMP9MMP14
SCHEMBL6138407 0.88 TRPA1 (0.65) MMP12MMP13MMP2MMP9MMP14
SCHEMBL10535065 0.88 TRPA1 (0.65) MMP12MMP13MMP2MMP9MMP14
SCHEMBL1861755 0.88 TRPA1 (0.65) MMP12MMP13MMP2MMP9MMP14
SCHEMBL11833496 0.86 MMP12 (0.53) MMP12MMP13MMP2MMP9MMP14
SCHEMBL11826750 0.86 MMP12 (0.53) MMP12MMP13MMP2MMP9MMP14
SCHEMBL11828044 0.86 MME (0.57) MMP12MMP13MMP2MMP9MMP14
SCHEMBL6808125 0.86 SRR (0.57) MMP12MMP13MMP2MMP9MMP14
SCHEMBL22677522 0.86 SRR (0.53) MMP12MMP13MMP2MMP9MMP14
SCHEMBL11828218 0.84 MMP12 (0.72) MMP12MMP13MMP2MMP9MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846910-B2 Matrix metalloproteinase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2014-09-30 US disclosed
US-8816073-B2 Matrix metalloproteinase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2014-08-26 US disclosed
US-8710261-B2 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases RANBAXY LABORATORIES LIMITED (IN) 2014-04-29 US disclosed
US-20130302378-A1 MATRIX METALLOPROTEINASE INHIBITORS SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2013-11-14 US disclosed
US-20130295141-A1 MATRIX METALLOPROTEINASE INHIBITORS SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2013-11-07 US disclosed
US-8507670-B2 Matrix metalloproteinase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2013-08-13 US disclosed
EP-2074093-B1 PROCESS FOR PREPARING MATRIX METALLOPROTEINASE INHIBITORS AND CHIRAL AUXILIARY THEREFOR RANBAXY LAB LTD (IN) 2012-10-10 EP disclosed
EP-2474531-A2 Matrix metalloproteinase inhibitors Ranbaxy Laboratories Limited (IN) 2012-07-11 EP disclosed
EP-1856063-B1 5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES RANBAXY LAB LTD (IN) 2012-01-25 EP disclosed
EP-2322507-A1 Matrix metalloproteinase inhibitors Ranbaxy Laboratories Limited (IN) 2011-05-18 EP disclosed
US-20100081610-A1 MATRIX METALLOPROTEINASE INHIBITORS SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2010-04-01 US disclosed
EP-2074093-A2 MATRIX METALLOPROTEINASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2009-07-01 EP disclosed
US-20080194565-A1 5-Phenyl-Pentanoic Acid Derivatives as Matrix Metalloproteinase Inhibitors for the Treatment of Asthma and Other Diseases SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2008-08-14 US disclosed
WO-2008023336-A2 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2008-02-28 WO disclosed
EP-1856063-A1 5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES Ranbaxy Laboratories Limited (IN) 2007-11-21 EP disclosed
WO-2006090235-A1 5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES RANBAXY LABORATORIES LIMITED (IN) 2006-08-31 WO disclosed
US-4529737-A Analgesic and anti-inflammatory arylalkanoic acid phthalidyl esters and pharmaceutical compositions thereof RESFAR S.R.I. (IT) 1985-07-16 US disclosed
US-4391814-A Derivatives of antiphlogistically effective carboxylic acids, their preparation and medicinal use SCHERING AKTIENGESELLSCHAFT (DE) 1983-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130302378-A1 MATRIX METALLOPROTEINASE INHIBITORS MMP9, MMP8, MMP25 MMP12 5/4885MMP13 7/4885MMP2 11/4885
US-20130295141-A1 MATRIX METALLOPROTEINASE INHIBITORS MMP9, MMP8, MMP25 MMP12 5/4885MMP13 7/4885MMP2 11/4885
US-20100081610-A1 MATRIX METALLOPROTEINASE INHIBITORS MMP9, MMP8, MMP12 MMP12 3/4885MMP13 7/4885MMP2 11/4885
US-20080194565-A1 5-Phenyl-Pentanoic Acid Derivatives as Matrix Metalloproteinase Inhibitors for the Treatment of Asthma and Other Diseases F2RL3, ACOX3, LPAR5 MMP12 15/4885MMP13 8/4885MMP2 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.